绝经后受体阳性乳腺癌患者高危人群的内分泌治疗PPT课件.pptVIP

绝经后激素受体阳性乳腺癌患者高危人群的内分泌治疗;ER阳性患者预后;Long-Term Risk of Breast Cancer;Clinical trials;高危人群;HER2阳性患者预后较差;Ki-67;*;21-Gene Recurrence Score Assay forPostmenopausal, ER(+) Breast Cancer;;;;;;;高危人群 风险控制;高危人群 风险控制;ATAC;Relationship of ER level and response to ET;;;;;高危人群 风险控制;BIG1-98 序贯;;高危人群 风险控制;Pooled analysis ATLAS + aTTom:br /Breast Cancer Mortality;Extended Adjuvant Therapy with AIsbr /br /;Slide 13;Slide 14;Longer-Term Outcomes of Letrozole v. Placebo After 5Years of Tamoxifen in the MA.17 Trial: br /Analyses Adjusting for Treatment Crossover;MA17;Slide 17;;Slide 19;Slide 20;Slide 21;How Long Is Long Enough? br /Defining Optimal Duration and Selection of Adjuvant Endocrine Therapy ;Conclusionbr /So What do We Do As Clinicians?;;;;;;;;;副作用-ATAC;副作用 BIG1-98;副作用-IES;Value-Based Approach to Systemic Therapy in Patients with Breast Cancer: What is the Evidence?;What do we get for what we spend?;Value?;Valuable treatments should produce outcomes that reflect meaningful clinical benefit to patients;